Gefitinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Gefitinib: From EGFR-Mutant Non-Small Cell Lung Cancer to Fibromatosis, Gingival
One-Sentence Summary
Gefitinib is an EGFR tyrosine kinase inhibitor used in EGFR-mutant non-small cell lung cancer (NSCLC) — this is drawn from literature captured in this evidence pack, as formal indication/licence text was not available. The TxGNN model predicts a possible link to Fibromatosis, Gingival, a benign gum tissue overgrowth condition, but this direction is currently supported by 0 clinical trials and 0 publications, and the model’s own generated rationale flags it as a likely spurious association.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | EGFR-mutant non-small cell lung cancer (NSCLC) (inferred from literature within this pack; TFDA/TGA licence text not available — Data Gap) |
| Predicted New Indication | Fibromatosis, Gingival |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Gefitinib in this evidence pack (flagged as a High-severity data gap). Based on literature captured elsewhere in this pack, Gefitinib is an EGFR tyrosine kinase inhibitor whose established efficacy is in EGFR-mutant NSCLC, where it blocks EGFR-driven proliferative signalling in tumour epithelium.
Gingival fibromatosis is a benign, non-neoplastic overgrowth of gingival connective tissue, mechanistically distinct from EGFR-driven epithelial malignancy. The evidence pack’s own model-generated rationale for this candidate states directly that there is “no known direct link” between the two, and that the high TxGNN score reflects a pure knowledge-graph prediction with no supporting evidence.
Taken together, the pharmacological rationale for this specific pairing is weak: a high similarity score from the prediction model has not been corroborated by any clinical, preclinical, or case-level literature. This pattern — high model score paired with no retrievable evidence — is consistent with a knowledge-graph artefact rather than a genuine repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (EGFR tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Please refer to the Product Information (PI) warnings and precautions |
| Handling Protection | Please refer to the Product Information (PI) warnings and precautions |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN prediction score, there is no clinical trial, literature, or mechanistic evidence connecting Gefitinib to gingival fibromatosis, and the model’s own rationale identifies this as a likely false-positive knowledge-graph association. No Taiwan/TGA licensing or safety data exists to support even a preliminary safety review.
To proceed, the following is needed:
- TFDA/TGA-approved Product Information, including warnings and contraindications (currently a Blocking data gap)
- Confirmed mechanism of action data for Gefitinib (currently a High-severity data gap)
- Any preclinical or case-level evidence specifically linking EGFR-TKI therapy to gingival fibromatosis, before this candidate can move past S0
Note: Within this same evidence pack, three other candidates — lung hilum carcinoma (rank 5), lung germ cell tumor (rank 8), and pulmonary sulcus neoplasm (rank 9) — are anatomic subtypes or regions of NSCLC and show closer mechanistic alignment with Gefitinib’s established EGFR-driven indication. These may warrant a separate, dedicated evaluation report rather than being assessed under the top TxGNN-ranked candidate.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.